MedImmune's Investigational Intranasal Influenza Vaccine, CAIV-T (cold adapted influenza vaccine, trivalent) Led to Higher Antibody Responses in Young Children Compared to Injectable

Filed in archive Treatment on October 17, 2006

A study recently announced by MedImmune, Inc. (Nasdaq: MEDI) revealed higher influenza serum antibody responses in children receiving the company's next-generation, investigational intranasal influenza vaccine, CAIV-T (cold adapted influenza vaccine, trivalent), than in children who received the traditional injectable trivalent inactivated flu vaccine (TIV).

The said results have been recently presented at the 44th Annual Meeting of the Infectious Diseases Society of America (IDSA).

According to Robert Belshe, M.D., director of the Center for Vaccine Development at Saint Louis University School of Medicine:

"These data are consistent with the results from our Phase 3 study conducted during the 2004-2005 season that demonstrated CAIV-T's increased efficacy against matched and mismatched strains in children under five years of age compared to TIV."

CAIV-T is MedImmune's investigational intranasal, cold-adapted trivalent influenza vaccine -- the refrigerator-stable formulation of FluMist®- a frozen, live attenuated cold-adapted trivalent influenza vaccine.

Find more details from MedImmune's press release.